Berlin (Germany) and Germantown, MD (U.S.A.), November 8, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that Nicholas T. Potter, PhD, FACMG has accepted the role of Director of Reimbursement and Medical Affairs effective November 1, 2017. Nick brings with him 25 years of experience in the delivery of MDx clinical services in both academic and commercial environments.
In his role at Epigenomics, he will establish the strategic approach to payers for the blood based menu of methylated cancer detection technologies. Nick will interact with MDx thought leaders on key clinical issues. Additionally, he will represent the voice of the customer in our development and lead our technical support efforts.
Most recently, Nick spent over 14 years at MPLN, Inc. in Maryville, TN as the Laboratory’s Director of Molecular Diagnostics, CSO, and finally EVP of Clinical Affairs. At the executive level at MPLN he played a pivotal role in driving value and strategic growth by pursuing business partnerships with IVD manufacturers, BioPharma, molecular diagnostics companies, and other CLIA certified/CAP accredited laboratories to allow access to new platforms, technologies, MDx tests, and clinical trials in addition to leading payment efforts focusing on women’s health, genomics, oncology and personalized medicine. Additionally, over this time frame, he served as a CAP inspector for molecular diagnostic laboratories.
Nick received his PhD from Duke University in immunology in 1986 following his undergraduate education at Bucknell University. He held post-graduate positions at Harvard, University of Connecticut and the University of Tennessee where he maintains a faculty appointment.
“We are pleased to have Nick as part of our team and look forward to his future contributions. Nick’s expertise in reimbursement and medical affairs will be a significant benefit as Epigenomics expands its commercial efforts. He truly understands the issues that impact the successful delivery of new molecular diagnostic tests” added Greg Hamilton, CEO of Epigenomics AG.
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: email@example.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.